US Edition
Research Analysts’ Recent Ratings Updates for Prime Medicine (PRME)
Summary by watchlistnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
tickerreport.comReposted by 
watchlistnews.com
watchlistnews.comResearch Analysts’ Recent Ratings Updates for Prime Medicine (PRME)
Prime Medicine (NYSE: PRME) recently received a number of ratings updates from brokerages and research firms: 5/27/2025 – Prime Medicine had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $1.50 price target on the stock, down previously from $10.00. 5/20/2025 – Prime Medicine was downgraded by analysts at HC Wainwright […]
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
